Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies

被引：0
|
作者：
Xenofon Baraliakos
Filip Van den Bosch
Pedro M. Machado
Lianne S. Gensler
Helena Marzo-Ortega
Bintu Sherif
Erhard Quebe-Fehling
Brian Porter
Corine Gaillez
Atul Deodhar
机构：
[1] Ruhr-University Bochum,Rheumazentrum Ruhrgebiet Herne
[2] Ghent University,Department of Internal Medicine and Pediatrics
[3] VIB Center for Inflammation Research,Department of Rheumatology
[4] University College London Hospitals NHS Foundation Trust,Department of Rheumatology, Northwick Park Hospital
[5] London North West University Healthcare NHS Trust,Centre for Rheumatology and Department of Neuromuscular Diseases
[6] University College London,Department of Medicine/Rheumatology
[7] University of California,NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds Institute of Rheumatic and Musculoskeletal Medicine
[8] San Francisco,undefined
[9] University of Leeds,undefined
[10] RTI Health Solutions,undefined
[11] Novartis Pharma AG,undefined
[12] Novartis Pharmaceuticals Corporation,undefined
[13] Oregon Health and Science University,undefined
来源：
Rheumatology and Therapy | 2021年 / 8卷
关键词：
Ankylosing spondylitis; Axial spondyloarthritis; Biologics; Interleukin-17; Low disease activity; Patient-reported outcomes; Remission; Secukinumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：273 / 288
页数：15
相关论文
共 50 条
  • [31] Impact of Age and Disease Duration on the Response to IL-17A Inhibitor (Secukinumab) Treatment in Ankylosing Spondylitis: Pooled Results from the Phase 3 MEASURE Studies
    Deodhar, Atul
    Mease, Philip
    Machado, Paula
    Meng, Xiangyi
    Strand, Vibeke
    Magrey, Marina
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [32] The Impact of Age and Time Since Diagnosis on Response to Treatment with Secukinumab in Pooled Week 52 Data from 4 Phase 3 Studies in Patients with Ankylosing Spondylitis
    Deodhar, Atul
    Mease, Philip
    Machado, Paula
    Pournara, Effie
    Meng, Xiangyi
    Strand, Vibeke
    Magrey, Marina
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [33] Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study
    Marzo-Ortega, H.
    Sieper, J.
    Kivitz, A.
    Blanco, R.
    Cohen, M.
    Martin, R.
    Readie, A.
    Richards, H. B.
    Porter, B.
    ARTHRITIS CARE & RESEARCH, 2017, 69 (07) : 1020 - 1029
  • [34] Effect of Long-Term Treatment with Secukinumab on Cardio-Metabolic Profile in Patients with Active Ankylosing Spondylitis and Psoriatic Arthritis: Pooled 3 Year Analysis
    McInnes, Iain
    Gladman, Dafna
    Deodhar, Atul
    Miceli-Richard, Corinne
    Nash, Peter
    Sattar, Naveed
    Mehta, Nehal
    Asquith, Darren
    Wang, Jianyuan
    Richards, Hanno
    Pricop, Luminita
    Shete, Abhijit
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [35] EFFECT OF SECUKINUMAB ON SPINAL RADIOGRAPHIC CHANGES THROUGH 2 YEARS IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS OF THE PHASE 3 STUDY, MEASURE-1
    Braun, J.
    Baraliakos, X.
    Deodhar, A.
    Baeten, D.
    Sieper, J.
    Emery, P.
    Talloczy, Z.
    Martin, R.
    Richards, H. B.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : 781 - 782
  • [36] Secukinumab Provides Rapid and Sustained Resolution of Enthesitis in Psoriatic Arthritis Patients: Pooled Analysis of Two Phase 3 Studies
    Coates, Laura C.
    McGonagle, Dennis
    Schett, Georg
    Mease, Philip J.
    Quebe-Fehling, Erhard
    Asquith, D. L.
    Rasouliyan, L.
    Mpofu, Shephard
    Gaillez, Corine
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [37] Effect of Interleukin-17A Inhibition on Spinal Radiographic Changes through 2 Years in Patients with Active Ankylosing Spondylitis: Results of a Phase 3 Study with Secukinumab
    Baraliakos, Xenofon
    Deodhar, Atul A.
    Braun, Juergen
    Baeten, Dominique
    Dougados, Maxime
    Sieper, Joachim
    Emery, Paul
    Readie, Aimee
    Martin, Ruvie
    Mpofu, Shephard
    Richards, Hanno
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [38] SECUKINUMAB PROVIDES SUSTAINED REDUCTION IN FATIGUE IN PATIENTS WITH ANKYLOSING SPONDYLITIS THROUGH 3 YEARS: LONG-TERM RESULTS OF TWO RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 STUDIES
    Kvien, T. K.
    Deodhar, A.
    Gossec, L.
    Conaghan, P. G.
    Strand, V.
    Ostergaard, M.
    Williams, N.
    Porter, B.
    Gandhi, K.
    Jugl, S.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S9 - S9
  • [39] SECUKINUMAB PROVIDES SUSTAINED REDUCTION IN FATIGUE IN PATIENTS WITH ANKYLOSING SPONDYLITIS THROUGH 3 YEARS: LONG-TERM RESULTS OF TWO RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 STUDIES
    Kvien, T. K.
    Deodhar, A.
    Gossec, L.
    Conaghan, P. G.
    Strand, V.
    Ostergaard, M.
    Williams, N.
    Porter, B.
    Gandhi, K.
    Jugl, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 355 - 356
  • [40] Reduction in fatigue in patients with active psoriatic arthritis is sustained over 2 years: long-term results of two phase 3 studies of secukinumab
    Kvien, T. K.
    Gossec, L.
    Conaghan, P.
    Ostergaard, M.
    Canete, J.
    Gaillez, C.
    Mpofu, S.
    Davenport, E.
    Jugl, S.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2016, 45 : 33 - 33
12345